A Phase II Trial of STI571 for the Treatment of Platinum and Taxane Refractory Stage III and IV Epithelial Ovarian Cancer and Primary Peritoneal Cancer

Histologically or pathologically confirmed epithelial carcinoma of the ovary or primary peritoneal serous papillary carcinoma, Stage III or IV, no mixed Mullerian Tumors, no borderline ovarian tumors, immunohistochemical tumor expression of KIT (CD117) and/or PDGFR , must have relapsed (or had a best response of increasing disease) within 6 months of frontline chemotherapy with platinum and taxane, measurable disease, besides the frontline platinum/taxane chemotherapy three additional prior chemotherapy regimens allowed, prior hormonal and/or biologic therapy allowed, prior radiation allowed (no more than 25% of bone marrow encompassed), PS 0-1, bilirubin <= 1.5 x IULN, SGOT/SGPT <= 2.5 x IULN, serum creatinine <= 1.5 x IULN, ANC >= 1,500, platelets >= 100,000, hemoglobin >= 9 gm/dl, specimens available for pathology review and correlative studies, no Class 3/4 cardiac problems, no pregnancy or nursing, no coumadin, some prior malignancies allowed (e.g. basal cell, squamous cell, in situ cervical).